Hit with a tri­al fail­ure, Agenus brings out the ax to chop staff, re­or­ga­nize

Over the last few weeks Lex­ing­ton, MA-based Agenus has trad­ed in a part­ner­ship with In­cyte for some fast cash and fol­lowed up with a sting­ing set­back in the clin­ic, ac­knowl­edg­ing that its lead can­cer vac­cine flopped.

To­day, it’s time to re­struc­ture.

Agenus is clos­ing a site in Basel, cut­ting 50 staffers and con­sol­i­dat­ing in Cam­bridge, UK and Lex­ing­ton. Its R&D chief, Robert Stein, is leav­ing as well.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER